I. CALL TO ORDER
The meeting of the Benefits Committee was called to order at 9:01 a.m. by Trustee Osa Tui, Vice Chairperson, in the Hawaii Employer-Union Health Benefits Trust Fund (EUTF) Conference Room, 201 Merchant Street, Suite 1700, Honolulu, Hawaii, on Tuesday, March 15, 2022.

II. SELECTION OF COMMITTEE OFFICERS
Mr. Derek Mizuno informed the Committee that with the departure of Chairperson Laurel Johnston the Committee can appoint a new Chairperson.

MOTION was made and seconded to appoint Vice Chairperson Tui as the Benefits Committee Chairperson. (Ferguson-Miyamoto/Wataru) Trustee Roderick Becker raised concerns about not having representation from both the employer and employee trustee groups in meetings with carriers and development of the agenda.
Trustee Wesley Machida joined the meeting at 9:07 a.m. Mr. Derek Mizuno suggested that the Chair and Vice Chair come from different trustee groups and both attend any carrier and pre-Benefits Committee meetings, and both review the draft Committee agenda developed by EUTF staff. Additionally, no meetings are to be held with carriers or consultants without the prior approval of the Board or Committee.

MOTION was made and seconded to amend the MOTION and appoint Trustee Osa Tui as Chairperson and Trustee Wesley Machida as Vice Chairperson of the Benefits Committee. (Becker/Hidano) The motion to amend passed unanimously. (Employer Trustees-3/Employee-Beneficiary Trustees-4)

The amended motion to appoint Trustee Osa Tui as Chairperson and Trustee Wesley Machida as Vice Chairperson of the Benefits Committee. (Becker/Hidano) passed unanimously. (Employer Trustees-3/Employee-Beneficiary Trustees-4)

III. REVIEW OF MINUTES – February 10, 2022
The Benefits Committee reviewed the draft minutes of February 10, 2022.

MOTION was made and seconded to approve the minutes of February 10, 2022, as circulated. (Wataru/Ferguson-Miyamoto) The motion passed unanimously. (Employer Trustees-3/Employee-Beneficiary Trustees-4)

IV. NEW BUSINESS
A. CVS prescription drug plan changes
Ms. Diane Clausen and Ms. Carla Goetz with PSG summarized the proposed plan changes.

MOTION was made and seconded to recommend to the Board addition of the CVS RxSavings Program to the EUTF and HSTA VB active and non-Medicare retiree prescription drug plans administered by CVS effective July 1, 2022. (Wataru/Ferguson-Miyamoto) The motion passed unanimously. (Employer Trustees-2 YES Becker, Hidano, 1 ABSTAIN Machida/Employee-Beneficiary Trustees-4 YES Ferguson-Miyamoto, Fern, Tui, Wataru)

MOTION was made and seconded to recommend to the Board limiting the plan cost of prescription prenatal and pediatric multivitamins to $300 and $900 on 30 and 90-day supplies, respectively, under the EUTF active and non-Medicare retiree prescription drug plans administered by CVS effective July 1, 2022. (Wataru/Ferguson-Miyamoto) The motion passed unanimously. (Employer Trustees-2 YES Becker, Hidano, 1 ABSTAIN Machida/Employee-Beneficiary Trustees-4 YES Ferguson-Miyamoto, Fern, Tui, Wataru)

MOTION was made and seconded to recommend to the Board adding prior authorization criteria and quantity limits on the entire class of eye drops used to treat presbyopia under the EUTF active and non-Medicare retiree prescription drug plans administered by CVS effective July 1, 2022. (Wataru/Ferguson-Miyamoto) The motion failed. (Employer Trustees-2 YES Becker, Hidano, 1 NO Machida/Employee-Beneficiary Trustees-4 YES
Ferguson-Miyamoto, Fern, Tui, Wataru)

MOTION was made and seconded to recommend to the Board placing prior authorization criteria and quantity limits on Vuity (eye drops used to treat presbyopia) under the EUTF active and non-Medicare retiree prescription drug plans administered by CVS effective July 1, 2022. (Wataru/Ferguson-Miyamoto) The motion passed unanimously. (Employer Trustees-3/Employee-Beneficiary Trustees-3)

Trustee Audrey Hidano requested that PSG update the Committee on the cost of future drugs in this class.

MOTION was made and seconded to recommend to the Board placing prior authorization criteria and quantity limits on Opzelura under the EUTF active and non-Medicare retiree prescription drug plans administered by CVS effective July 1, 2022. (Wataru/Ferguson-Miyamoto) The motion failed. (Employer Trustees-2 YES Becker, Hidano, 1 NO Machida/Employee-Beneficiary Trustees-3 YES Ferguson-Miyamoto, Tui, Wataru)

MOTION was made and seconded to recommend to the Board extending the age limitation for coverage of colorectal prep prescription drugs to ages 45-75 in accordance with federal law under the EUTF and HSTA VB active prescription drug plans administered by CVS effective May 1, 2022. (Wataru/Ferguson-Miyamoto) The motion passed unanimously. (Employer Trustees-3/Employee-Beneficiary Trustees-3)

MOTION was made and seconded to reconsider the motion regarding the entire class of eye drops used for presbyopia. (Machida/Ferguson-Miyamoto). The motion passed unanimously. (Employer Trustees-3/Employee-Beneficiary Trustees-3)

MOTION was made and seconded to reconsider the motion regarding Opzelura. (Machida/Wataru). The motion passed unanimously. (Employer Trustees-3/Employee-Beneficiary Trustees-3)

MOTION was made and seconded to recommend to the Board placing prior authorization criteria and quantity limits on Opzelura under the EUTF active and non-Medicare retiree prescription drug plans administered by CVS effective July 1, 2022. (Wataru/Ferguson-Miyamoto) The motion passed unanimously. (Employer Trustees-3/Employee-Beneficiary Trustees-3)

MOTION was made and seconded to reconsider the motion regarding Opzelura. (Machida/Wataru). The motion passed unanimously. (Employer Trustees-3/Employee-Beneficiary Trustees-3)

MOTION was made and seconded to recommend to the Board placing prior authorization criteria and quantity limits on Opzelura under the EUTF active and non-Medicare retiree prescription drug plans administered by CVS effective July 1, 2022. (Wataru/Ferguson-Miyamoto) The motion passed unanimously. (Employer Trustees-3/Employee-Beneficiary Trustees-3)

B. PSG initial analysis report on the CVS/SilverScript prescription drug plans
Ms. Clausen, PSG, summarized their analysis and areas of focus over the upcoming contract period to be worked with EUTF staff and CVS/SilverScript related to current cost trends, cost drivers, benefit plan design, formulary, and generic dispensing rates.
V. NEXT MEETING DATE – May 16, 2022
The next meeting agenda will include HMSA, Kaiser Permanente and PSG utilization reports ending December 31, 2021.

VI. ADJOURNMENT
MOTION was made and seconded to adjourn the meeting at 10:14 a.m. (Wataru/Ferguson-Miyamoto) The motion passed unanimously. (Employer Trustees-3/Employee-Beneficiary Trustees-3)

Respectfully submitted,

/s/

Osa Tui, Chairperson

APPROVED on May 16, 2022.

Documents Distributed:
1. Draft Benefits Committee Minutes of February 10, 2022. (6 pages)
2. EUTF Active & Retiree Plans, Rx Plan Design Recommendations, prepared by PSG, dated March 9, 2022, Redacted Version. (12 pages)
3. EUTF Active & Retiree Plans, Rx Diagnostic, prepared by PSG, dated March 7, 2022, Redacted Version. (53 pages)